NRG-HN016: The "CONCISE" Study for Locoregionally Advanced Head and Neck Cancer Patients that are Unable to Take Cisplatin
The NRG Oncology PodcastShow Notes
Our co-hosts interview the PI of the active NRG-HN016 (CONCISE) trial, Dr. Loren Mell. The CONCISE study is a randomized phase III trial comparing radiation therapy (RT) plus carboplatin/paclitaxel vs. RT plus cetuximab for patients with locoregionally advanced head and neck cancer who have a contraindication to cisplatin. CONCISE is the first trial comparing the two most commonly used regimens for this population, and the first “pragmatic” trial for solid tumors to be conducted by NRG Oncology.
More from The NRG Oncology Podcast
For Breast Cancer Awareness Month, we discuss the results of the NRG-BR002 in newly oligometastatic breast cancer published in the Journal of Clinical Oncology today.
We discuss the reported results of the NRG-HN009 p16-negative cohort presented at the ASTRO Annual Meeting Late-Breaking Abstract Session.
We discuss both the NRG-CC009 study results presented during the 2026 ASTRO Annual Meeting Plenary Session and the MAVERICK study results presented during the Clinical Trials Session.
We discuss the NRG-GI003 results presented during the 2026 ASTRO Annual Meeting Plenary Session.
We interview Dr. Shang "George" Zhao on the NRG-RTOG 0534 "SPPORT" study results he presented at the 2026 ASTRO Annual Meeting Clinical Trials Session.